First clinical use of Colibri's TAVI system

Source：Colibri Heart Valve, LLC Release Date：2012-12-07 272

Medical Equipment

Colibri’s transcatheter aortic heart valve implanted for first time in human patient

Colibri Heart Valve has announced the successful completion of the first clinical use of the company’s proprietary transcatheter aortic heart valve. The Colibri transcatheter aortic valve implantation (TAVI) system is the world’s first and only low profile, 14 French pre-mounted, pre-crimped, and pre-packaged, ready-for-use TAVI system.

“The successful first-in-patient implantation of this breakthrough TAVI system is a significant and exciting milestone for our company,” stated Joseph B. Horn, Colibri’s president and chief executive officer. “While there have been many advancements in TAVI technology in recent years, we believe the advantages offered to physicians and hospitals by the Colibri TAVI system have the potential to measurably simplify and reduce pre-procedure preparation time and therefore overall cost. In addition, we believe the low profile 14 French introducer used in our system has the potential to be used in patients not currently considered TAVI candidates due to the relatively small diameter of their femoral arteries, thereby increasing the number of TAVI femoral patients who may benefit from this procedure."

Dr. Pedro Ure?a, director of the Cardiovascular Department at the Center of Advanced Medicine (CEDIMAT) in Santo Domingo, Dominican Republic, performed the procedure last week on a female patient with extensive calcification of the aortic valve. The treatment is part of Colibri’s first-in-human feasibility study of the 24 mm Colibri aortic heart valve and delivery system.Browse All Brands